Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).www.regeneron.com
125
MENTIONS
81
EPISODES
64
PODCASTS
Search complete. 125 mentions across 81 episodes found for "Regeneron Pharmaceuticals".
Oct 30, 2026
Cathy AntunesHOST
I mean, of course, right? We all want to have our personal choice.
Cathy AntunesHOST
But, you know, one of the ways what I saw was that the Regeneron monoclonal antibody for COVID, when it came out, our governor was promoting that, which made sense.
Cathy AntunesHOST
to an extent.
Cathy AntunesHOST
But at the same time, just knowing from the marketing in pharmaceuticals, one of the ways you expand the market is to expand the number of patients.
Ehsan RahimyGUEST
We have big pharma in the room, right? Merck acquired iBio.
Ehsan RahimyGUEST
There's Regeneron.
Ehsan RahimyGUEST
There's Genentech, Roche.
Ehsan RahimyGUEST
But then there's much smaller companies.
Phil RosenHOST
I'll take and okay So I was looking at the names you have in health care.
Phil RosenHOST
Yeah And you shared a couple but I saw Merck Regeneron of course at pharmaceuticals One name I did not see was Eli Lilly.
Phil RosenHOST
Yep.
Phil RosenHOST
That is I own that stock.
Steve SwanHOST
Right.
Steve SwanHOST
Because when I had a conversation in one of my previous podcasts with Bob McGowan, who is the CIO up at Regeneron, I placed him up there and I asked him, I asked him, you know, near the end of our conversation, I said, if I were a CIO of a small biotech right now.
Steve SwanHOST
What did you not know when you started there that you wish you knew now? Or what advice would you give me? He said, that's easy.
Steve SwanHOST
Get your data ready.
Steve SwanHOST
Now, I bet some of the things you would get, which I know that my audience would want to think about or talk about, is security, right? So, I mean, obviously, you're not physically there and you're there doing your thing, right? But you're not physically...
Steve SwanHOST
So...
Steve SwanHOST
How do you handle that? Where do you go with that? I mean, you know, because if I work at Regeneron or I work wherever, I'm like, this is mine, man.
Steve SwanHOST
I don't want anybody getting a hold of this.
Brent SlavaHOST
We use ETF channel, but you can use any provider that you can find holdings and you go type in QQQ and you find all the components here that aren't attached closely to tech like a Vertex VRTX.
Brent SlavaHOST
We got through this list, Dennis, I think down to this page, Honeywell, Regeneron.
Brent SlavaHOST
I can't find
Dennis DickHOST
one that's down.
Ron ElfenbeinGUEST
Why would you not allow them in the hospitalized patients? In, in the Emergency Use Authorization specifically says you cannot give them to hospitalized patients.
Ron ElfenbeinGUEST
Regeneron, which is, which is what Trump got, okay? Which what saved President Trump's life, per his own admission.
Ron ElfenbeinGUEST
They did this study called the Recovery Study in June of 2021, and it showed a 20% reduction in mortality in hospitalized patients.
Ron ElfenbeinGUEST
That means 20% less people died in the hospital when they were given monoclonal antibodies.
Tahamtan AhmadiGUEST
In the early 2000s, there was a first innovation that basically tried to not humanize mouse antibodies, but generate essentially human sequences in the mouse, and this required the innovation and the invention of a transgenic mouse, and this is a little bit where the story of GemUp comes in.
Tahamtan AhmadiGUEST
GemUp, as a spin-out of Medarex back then, one of the two companies, if you will, on two mice, the original foundational technology went to Regeneron, a lab, and then there was the Metarex mouse that became the GemUp mouse.
Tahamtan AhmadiGUEST
And these were the first innovation trying to make human antibodies under the idea that if you would stick more closely to a human antibody structure, you may be able to elicit even better responses.
Tahamtan AhmadiGUEST
That, body speaking, didn't really play out the way it was envisioned.
Jim DornhofferGUEST
I think one of the biggest kind of lateral leaps, though, is we are seeing a lot of success with some new gene therapies.
Jim DornhofferGUEST
The most popular, most people may have read about in the news is Otofralin gene therapy out of a company, Regeneron, just got FDA approval for that.
Jim DornhofferGUEST
That's definitely not a one-size-fits-all.
Jim DornhofferGUEST
That's going to be for specific patients with specific gene defects, but it is certainly kind of a very powerful proof of concept that we can manipulate a lot of the common causes of genetic or congenital hearing loss, so hearing loss you're born with.
Dean MitchellHOST
They also put in millions and millions of dollars into vaccinations.
Dean MitchellHOST
I mean, look at, I think it was the company Regeneron.
Dean MitchellHOST
During the COVID pandemic, their stock was flying off the charts.
Dean MitchellHOST
And then post-COVID, when everybody stopped getting the vaccines for the most part, their stock was in the tank.
Gary KaltbaumHOST
This is Friday.
Gary KaltbaumHOST
The CBOE, Regeneron Pharmaceuticals, Exxon, Colgate.
Gary KaltbaumHOST
That's nothing.
Gary KaltbaumHOST
Wait till next week.
71 more episodes mention Regeneron Pharmaceuticals.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.